(NYSEMKT: NRXS) Neuraxis's forecast annual revenue growth rate of 76.57% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 47.2%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.89%.
Neuraxis's revenue in 2026 is $5,316,119.On average, 4 Wall Street analysts forecast NRXS's revenue for 2026 to be $112,768,730, with the lowest NRXS revenue forecast at $102,144,861, and the highest NRXS revenue forecast at $122,714,480. On average, 3 Wall Street analysts forecast NRXS's revenue for 2027 to be $265,144,650, with the lowest NRXS revenue forecast at $254,746,821, and the highest NRXS revenue forecast at $272,943,022.
In 2027, NRXS is forecast to generate $253,616,622 in revenue, with the lowest revenue forecast at $243,670,872 and the highest revenue forecast at $261,075,934.